Pattern and implications of neurological examination findings in autosomal dominant Alzheimer disease.
Alzheimer disease
autosomal dominant Alzheimer disease
differential diagnosis
neurological examination
neurological examination findings
predictive value
prognosis
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
revised:
21
03
2022
received:
21
09
2021
accepted:
27
03
2022
pmc-release:
01
02
2024
pubmed:
25
5
2022
medline:
18
2
2023
entrez:
24
5
2022
Statut:
ppublish
Résumé
As knowledge about neurological examination findings in autosomal dominant Alzheimer disease (ADAD) is incomplete, we aimed to determine the frequency and significance of neurological examination findings in ADAD. Frequencies of neurological examination findings were compared between symptomatic mutation carriers and non mutation carriers from the Dominantly Inherited Alzheimer Network (DIAN) to define AD neurological examination findings. AD neurological examination findings were analyzed regarding frequency, association with and predictive value regarding cognitive decline, and association with brain atrophy in symptomatic mutation carriers. AD neurological examination findings included abnormal deep tendon reflexes, gait disturbance, pathological cranial nerve examination findings, tremor, abnormal finger to nose and heel to shin testing, and compromised motor strength. The frequency of AD neurological examination findings was 65.1%. Cross-sectionally, mutation carriers with AD neurological examination findings showed a more than two-fold faster cognitive decline and had greater parieto-temporal atrophy, including hippocampal atrophy. Longitudinally, AD neurological examination findings predicted a significantly greater decline over time. ADAD features a distinct pattern of neurological examination findings that is useful to estimate prognosis and may inform clinical care and therapeutic trial designs.
Identifiants
pubmed: 35609137
doi: 10.1002/alz.12684
pmc: PMC9684350
mid: NIHMS1796820
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
632-645Subventions
Organisme : NINDS NIH HHS
ID : R01 NS114382
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG068319
Pays : United States
Organisme : NIA NIH HHS
ID : R21 AG064776
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG066462
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG054567
Pays : United States
Organisme : NIA NIH HHS
ID : K23 AG064029
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG053267
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG054513
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG052550
Pays : United States
Organisme : NIA NIH HHS
ID : U2C AG057441
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG066444
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG067505
Pays : United States
Organisme : NINR NIH HHS
ID : R01 NR017571
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG051218
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG064584
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG054536
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG036694
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB028297
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG053550
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG003991
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS075321
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG056573
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG024904
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG066530
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG060929
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG025340
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS067443
Pays : United States
Organisme : NIA NIH HHS
ID : UF1 AG032438
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS097799
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG062007
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG071865
Pays : United States
Organisme : NINDS NIH HHS
ID : UH3 NS100614
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG052350
Pays : United States
Organisme : NIA NIH HHS
ID : R21 AG065753
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG066711
Pays : United States
Organisme : NIA NIH HHS
ID : T35 AG044303
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG062667
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG032438
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG070883
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS092865
Pays : United States
Organisme : Medical Research Council
ID : MR/L023784/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/009076/1
Pays : United Kingdom
Informations de copyright
© 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Gowers W. A manual of diseases of the nervous system. London : J. & A. Churchill.1888
Fox MD. Mapping symptoms to brain networks with the human connectome. N Engl J Med 2018;379(23):2237-2245. https://doi.org/10.1056/NEJMra1706158
Nicholl DJ, Appleton JP. Clinical neurology: why this still matters in the 21st century. J Neurol Neurosurg Psychiatry 2015;86(2):229-233. https://doi.org/10.1136/jnnp-2013-306881
Hampton JR, Harrison MJ, Mitchell JR, Prichard JS, Seymour C. Relative contributions of history-taking, physical examination, and laboratory investigation to diagnosis and management of medical outpatients. Br Med J 1975;2(5969):486-489. https://doi.org/10.1136/bmj.2.5969.486
Paley L, Zornitzki T, Cohen J, Friedman J, Kozak N, Schattner A. Utility of clinical examination in the diagnosis of emergency department patients admitted to the department of medicine of an academic hospital. Arch Intern Med 2011;171(15):1393-1400. https://doi.org/10.1001/archinternmed.2011.340
Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367(9):795-804. https://doi.org/10.1056/NEJMoa1202753
Storandt M, Balota DA, Aschenbrenner AJ, Morris JC. Clinical and psychological characteristics of the initial cohort of the Dominantly Inherited Alzheimer Network (DIAN). Neuropsychology 2014;28(1):19-29. https://doi.org/10.1037/neu0000030
Ryan NS, Nicholas JM, Weston PSJ, et al. Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer's disease: a case series. Lancet Neurol 2016;15(13):1326-1335. https://doi.org/10.1016/s1474-4422(16)30193-4
Tang M, Ryman DC, McDade E, et al. Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurol 2016;15(13):1317-1325. https://doi.org/10.1016/s1474-4422(16)30229-0
Johnson DK, Storandt M, Morris JC, Galvin JE. Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol 2009;66(10):1254-1259. https://doi.org/10.1001/archneurol.2009.158
Vöglein J, Kostova I, Arzberger T, et al. First symptom guides diagnosis and prognosis in neurodegenerative diseases-a retrospective study of autopsy proven cases. Eur J Neurol 2021;28(6):1801-1811. Portico. https://doi.org/10.1111/ene.14800
Hauser WA, Morris ML, Heston LL, Anderson VE. Seizures and myoclonus in patients with Alzheimer's disease. Neurology 1986;36(9):1226-1230. https://doi.org/10.1212/wnl.36.9.1226
Vöglein J, Noachtar S, McDade E, et al. Seizures as an early symptom of autosomal dominant Alzheimer's disease. Neurobiol Aging 2019;76:18-23. doi:https://doi.org/10.1016/j.neurobiolaging.2018.11.022
Vöglein J, Paumier K, Jucker M, et al. Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease. Brain 2019;142(5):1429-1440. https://doi.org/10.1093/brain/awz050
Vöglein J, Ricard I, Noachtar S, et al. Seizures in Alzheimer's disease are highly recurrent and associated with a poor disease course. J Neurol 2020;267(10):2941-2948. https://doi.org/10.1007/s00415-020-09937-7
Vöglein J, Kostova I, Arzberger T, et al. Seizure prevalence in neurodegenerative diseases-a study of autopsy proven cases. Eur J Neurol 2021;29(1):12-18. Portico. https://doi.org/10.1111/ene.15089
Jack CR, Jr., Wiste HJ, Weigand SD, et al. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. Lancet Neurol 2017;16(6):435-444. https://doi.org/10.1016/s1474-4422(17)30077-7
McDade E, Wang G, Gordon BA, et al. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology 2018;91(14):e1295-e1306. https://doi.org/10.1212/wnl.0000000000006277
Levin J, Vöglein J, Quiroz YT, et al. Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease. Alzheimers Dement 2022;18(12):2687-2698. https://doi.org/10.1002/alz.12624
Bateman RJ, Aisen PS, De Strooper B, et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther 2011;3(1):1. https://doi.org/10.1186/alzrt59
Cairns NJ, Perrin RJ, Franklin EE, et al. Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). Neuropathology 2015;35(4):390-400. https://doi.org/10.1111/neup.12205
Ringman JM, Monsell S, Ng DW, et al. Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database. J Neuropathol Exp Neurol 2022;18(12):2687-2698. https://doi.org/10.1093/jnen/nlv028
Ryman DC, Acosta-Baena N, Aisen PS, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 2014;83(3):253-260. https://doi.org/10.1212/wnl.0000000000000596
Hanewinckel R, van Oijen M, Ikram MA, van Doorn PA. The epidemiology and risk factors of chronic polyneuropathy. Eur J Epidemiol 2016;31(1):5-20. https://doi.org/10.1007/s10654-015-0094-6
Tinetti ME, Kumar C. The patient who falls: “It's always a trade-off”. Jama 2010;303(3):258-266. https://doi.org/10.1001/jama.2009.2024
Grecula MJ, Caban ME. Common orthopaedic problems in the elderly patient. J Am Coll Surg 2005;200(5):774-783. https://doi.org/10.1016/j.jamcollsurg.2004.12.003
Schott JM. The neurology of ageing: what is normal? Pract Neurol 2017;17(3):172-182. https://doi.org/10.1136/practneurol-2016-001566
Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 2006;20(4):210-216. https://doi.org/10.1097/01.wad.0000213865.09806.92
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43(11):2412-2414.
Marsh JL, Hutton JL, Binks K. Removal of radiation dose response effects: an example of over-matching. BMJ 2002;325(7359):327. https://doi.org/10.1136/bmj.325.7359.327
Desikan RS, Ségonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. NeuroImage 2006;31(3):968-980. https://doi.org/10.1016/j.neuroimage.2006.01.021
Cedarbaum JM, Jaros M, Hernandez C, et al. Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials. Alzheimers Dement 2013;9(1 Suppl):S45-S55. https://doi.org/10.1016/j.jalz.2011.11.002
Gordon BA, Blazey TM, Su Y, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurol 2018;17(3):241-250. https://doi.org/10.1016/s1474-4422(18)30028-0
Popper K, Miller D. A proof of the impossibility of inductive probability. Nature 1983;302(5910):687-688. https://doi.org/10.1038/302687a0
Rosch E. Principles of categorization. In: Rosch E, Lloyd BB, eds. Cognition and Categorization. Lawrence Erlbaum Associates; 1978:27-48.
O'Bryant SE, Waring SC, Cullum CM, et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. Arch Neurol 2008;65(8):1091-1095. https://doi.org/10.1001/archneur.65.8.1091
Karlstrom H, Brooks WS, Kwok JB, et al. Variable phenotype of Alzheimer's disease with spastic paraparesis. J Neurochem 2008;104(3):573-583. https://doi.org/10.1111/j.1471-4159.2007.05038.x